To develop novel AI-, big data-, structure-, ligand-, Proteolysis targeting chimeras (PROTACs)-, multitarget-directed ligands (MTLDs)-, photoswitches-based strategies for drug discovery targeting CC alterations.
To develop novel drug delivery approaches for transport of small molecules, peptides, siRNAs across the BBB, and direct nose-to-brain (N-to-B) delivery, which take into consideration CC dysfunction.
To perform preclinical validation of drugs/targets modulating CC dysfunction in innovative in vitro (human 2D, 3D cultures, induced pluripotent stem cells (iPSCs) and organ-on-chip) & in vivo (Drosophila) AD models.
To get insight into the molecular mechanisms underlying CC in AD and associated drug response, in in vivo AD models (C. elegans & mice).
To develop an innovative biotech business model and impact strategies for the techniques/tools (and eventually products) developed in TClock4AD, and to explore their commercial and potential clinical applications.
